ADC Evaluation Service in Solid Tumor Models

Creative Biolabs provides a large variety of xenograft human cancer models and bioanalytical methods to support antibody-drug conjugate (ADC) therapeutic potential studies. With well-trained scientists with excellent surgical skills, extensive knowledge and expertise in in vivo experimentation, as well as advanced facilities and technological platform, we are dedicated to develop both orthotopic and subcutaneous xenograft models for various challenges in ADC in vivo evaluation projects.

Xenograft Tumor Model

Creative Biolabs is in possession of a diverse selection of immunodeficient mice for xenograft tumor model creation. Murine xenograft tumor models (heterotopic xenograft models and orthotopic xenograft models) are widely used for anti-cancer therapeutics studies to evaluate their tumor suppression capabilities against various solid tumors.

• Creation of heterotopic xenograft models:

Heterotopic xenograft models are developed by injecting tumor cells or malignant into thymic nude mice, severely compromised immunodeficient (SCID) mice, or other immunocompromised mice. Subcutaneous implantation is most common for these models and based on the quantity of injected cancer cells, tumor will form and growth within a short period of time (several weeks or months).

• Creation of orthotopic xenograft models:

To create orthotopic xenograft models, tumor cells or tissues are usually injected into the tumor originating organs of the immunodeficient mice. Similar to heterotopic xenograft models, tumor will emerge and develop within a short period of time to the desired sizes. Comparing to the heterotopic xenograft models, the orthotopic model is more advantageous in that the solid tumor exerts similar microenvironment as the original tumor and it is more suitable for metastasis studies.

Creative Biolabs maintains a wide variety of human cancer cell lines for xenograft tumor model development:

Information Derived from Xenograft Tumor Model

Various information regarding the efficacy of an ADC can be extrapolated using xenograft tumor models. Standard measurements include body weight change, food consumption, physiological tumor growth curve, tumor mass weight, and tumor suppression rate. Additional analysis, including ELISA & western blotting, immunohistochemistry, H&E staining, and RT-qPCR that evaluate more detailed impacts of the ADC on tumor can also be made to obtain a comprehensive picture of ADC in vivo efficacy.

Bioluminescent Xenograft Model

Tumor size and volume in subcutaneous xenograft model can be directly measured and calculated by vernier caliper. However, this method is not applicable for orthotopic or non-subcutaneous xegnograft models. Creative Biolabs offers non-invasive imaging systems to monitor tumor growth, metastatic dissemination, and response to therapeutic treatments. By transducing cancer cell to express firefly luciferase, implanted tumor cells can produce bioluminescent signal after injection of D-luciferin. Our experts are experienced in cancer cell transducing as well as imaging to offer efficient ADC efficacy assessments.

Orthotopic implantation of HT-29 colorectal tumor cells and bioluminescent imaging of mice model over time (J Mol Biol & Mol Imaging, 2015).

Reference：

1. Fernández, Y.; et al. Bioluminescent imaging of animal models for human colorectal cancer tumor growth and metastatic dissemination to clinically significant sites. J Mol Biol & Mol Imaging. 2015, 2(2): 1019.